Apigenin

GABA-A Receptor Modulation

Apigenin's most established pharmacological mechanism is partial positive allosteric modulation of GABA-A receptors. It binds to the benzodiazepine recognition site on GABA-A receptor complexes (the site where diazepam, alprazolam, and related drugs bind), but unlike full benzodiazepine agonists, produces only partial receptor activation.

This partial agonism profile has important implications:

• Anxiolytic and sedative effects: Present and dose-dependent, but submaximal relative to clinical benzodiazepines
• Muscle relaxation: Less pronounced than full agonists
• Anticonvulsant activity: Demonstrated in animal models
• Absence of full benzodiazepine side effects: No significant respiratory depression, amnesia, or tolerance/dependence liability at doses that produce anxiolysis — the key differentiator from clinical benzodiazepines

The Ki for apigenin binding at benzodiazepine sites is in the nanomolar range, making it a genuinely high-affinity binder at this site and supporting the relevance of GABA-A modulation at achievable brain concentrations.

CD38 Inhibition and NAD+ Preservation

CD38 is a multifunctional enzyme (ADP-ribosyl cyclase/hydrolase) that is a major consumer of cellular NAD+. During aging, CD38 expression increases significantly — an increase associated with tissue inflammation and inflammaging — and the resulting NAD+ consumption is believed to be a major contributor to the NAD+ decline of aging (alongside reduced biosynthesis via the NMN/NR pathway).

Apigenin inhibits CD38 enzyme activity, reducing NAD+ consumption. In mouse studies, apigenin supplementation increased tissue NAD+ levels. This positions apigenin as a mechanistically distinct complement to NAD+ precursor supplementation (NMN, NR):

• NMN and NR increase NAD+ supply (by providing precursors for de novo synthesis)
• Apigenin reduces NAD+ consumption (by inhibiting its major catabolic enzyme)

Estrogen Receptor Modulation

Apigenin modulates estrogen receptor activity — exhibiting estrogenic activity at ERβ and antiestrogenic activity at ERα. This selective estrogen receptor modulator (SERM)-like profile has implications for breast cancer biology and hormonal conditions, and should be considered in clinical contexts.

Anti-Inflammatory Mechanisms

• Inhibits NF-κB activation and downstream cytokine production
• Inhibits COX-2 and lipoxygenase (LOX) activity
• Activates Nrf2 pathway (modest, shared with other flavonoids)
• Inhibits NLRP3 inflammasome activation

Pharmacokinetics

Apigenin is absorbed from the GI tract, undergoes first-pass hepatic metabolism and gut bacterial deglycosylation (glycosidic forms abundant in food require bacterial hydrolysis to release aglycone). Bioavailability is moderate; food matrix and gut microbiome composition significantly affect absorption. Plasma half-life is approximately 6–12 hours. Apigenin and its metabolites are excreted in urine and bile.

Ancient Use of Chamomile

Chamomile (Matricaria chamomilla and Anthemis nobilis) has been used medicinally for at least 5,000 years — one of the oldest documented herbal medicines. It appears in ancient Egyptian medical papyri (Ebers Papyrus, circa 1550 BCE), where it was used for fever and neurological conditions. The ancient Greeks called it anthemis ("earth apple") and used it widely for digestive complaints, anxiety, and sleep. Roman naturalist Pliny the Elder described its medicinal use in the 1st century CE.

Throughout European folk medicine, chamomile tea became the archetypal home remedy for sleeplessness, anxiety, and "nervous complaints" — a role it has maintained continuously to the present day, making it one of the most widely consumed herbal beverages globally. Its use as a sleep aid by German grandmothers, in particular, became culturally embedded enough to earn it the German designation Alles zutraut ("capable of anything").

Isolation and Characterization of Apigenin

Apigenin was first isolated from parsley in the 1930s by Polish chemist T. Suzuki and colleagues, who characterized it as a yellow crystalline flavone. Its presence in chamomile was characterized subsequently, and its GABA-A binding activity was first demonstrated in animal pharmacology studies in the early 1990s.

GABA-A Research

The first characterization of apigenin as a GABA-A benzodiazepine site ligand was published in 1994 by Viola et al. in Planta Medica, showing direct binding to the benzodiazepine recognition site and anxiolytic effects in mouse models without the sedation and muscle relaxation of full agonists. This work provided a molecular mechanism for the longstanding folk observation that chamomile was calming without being heavily sedating.

CD38 Inhibition Discovery

The discovery of apigenin as a CD38 inhibitor was published by Escande et al. in 2013 in Diabetes, identifying apigenin and quercetin as potent CD38 inhibitors that increased intracellular NAD+ levels. This finding connected apigenin to the emerging NAD+ biology and longevity research field, substantially expanding interest in apigenin beyond its traditional roles in anxiety and sleep support.